跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
LUXTURNA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
LUXTURNA
Authorized
STANDARD
LUXTURNA
novartis pharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f5670204792d681f
Company
novartis pharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
f5670204792d681f
Drug Approval Canada Name
LUXTURNA
Product Name
LUXTURNA
Status
Marketed
Status Date
2022-03-14
Original Market Date
2022-03-14
Din
02505851
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subretinal
Schedule
Prescription , Schedule D
Ahfs
26:12.00
Atc Original
S01XA27 VORETIGENE NEPARVOVEC
Atc Name
s 01 xa 27
Aig Number
0162520001
Company Name
novartis pharmaceuticals canada inc
Company Address
100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1
Active Ingredients
VORETIGENE NEPARVOVEC
5000000000000 VG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f5670204792d681f
Type
Standard
Back to Health Canada Approvals